Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.